Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity
2021 · Nature Communications · 91 citations
https://doi.org/10.1038/s41467-021-20973-3
A
Annika Nelde
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
127
Papers
2.7K
Citations
27
h-index
41
i10-index
Annika Nelde is an academic researcher from University Children's Hospital Tübingen. The author has contributed to research in topics: vaccines and immunoinformatics approaches & Immunotherapy and Immune Responses & Monoclonal and Polyclonal Antibodies Research. The author has an h-index of 27, co-authored 108 publications.
ORCID: 0000-0001-8504-8481Papers by this author
worksNeutrobodyPlex—monitoring SARS‐CoV‐2 neutralizing immune responses using nanobodies
2021 · EMBO Reports · 61 citations
https://doi.org/10.15252/embr.202052325
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency
2023 · Nature Communications · 33 citations
https://doi.org/10.1038/s41467-023-40758-0
Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma
2020 · Blood Cancer Journal · 21 citations
https://doi.org/10.1038/s41408-020-0288-3
Increased soluble HLA in COVID-19 present a disease-related, diverse immunopeptidome associated with T cell immunity
2022 · iScience · 11 citations
https://doi.org/10.1016/j.isci.2022.105643
Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivo
2020 · Cancer Immunology Immunotherapy · 9 citations
https://doi.org/10.1007/s00262-020-02519-6
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat